Control of cervical cancer: women's options and rights.

Int J Gynaecol Obstet

Brown University, Warren Alpert School of Medicine, Providence, RI 02905, USA.

Published: August 2009

Cervical cancer takes the lives of more than 250,000 women each year globally, particularly in under-resourced areas of low-, middle-, and high-income countries. Options for cancer control and treatment have reached a point that there are interventions for control that could be adopted for virtually every resource and demographic situation. Women die despite the availability of attractive control options, which means that educating policy makers, women's health professionals, as well as women themselves, must become a major focus for ongoing control of this disease. The human right to life, to prevention of suffering, and to education are all key rights linked to improving the control of cervical cancer and saving the lives of women, particularly in resource-poor parts of the world.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijgo.2009.03.027DOI Listing

Publication Analysis

Top Keywords

cervical cancer
12
control cervical
8
control
6
cancer
4
cancer women's
4
women's options
4
options rights
4
rights cervical
4
cancer takes
4
takes lives
4

Similar Publications

Objective: This study aimed to uncover the patterns of Human papillomavirus (HPV) infection outcomes in women and assess the risk factors that may affect these outcomes.

Methods: A retrospective study was conducted on 608 women who tested positive for HPV-DNA during their initial visit to the outpatient department of Shenzhen Longgang Central Hospital from 2018 to 2023 and who had subsequent HPV-DNA testing as part of their post-visit monitoring. The monitoring intervals were every 6 months.

View Article and Find Full Text PDF

Background: Cervical cancer is the most common gynaecological cancer worldwide, causing morbidity and mortality, especially in developing countries like Nigeria. It develops from premalignant lesions of the cervix. Human immune deficiency virus (HIV) increases the risk of dysplastic changes in the cervix.

View Article and Find Full Text PDF

Ocular surface disease related to tisotumab vedotin-tftv.

Gynecol Oncol Rep

February 2025

Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, United States.

Introduction: To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.

Methods: This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.

Results: Five patients were identified who developed ocular surface disease while on TV.

View Article and Find Full Text PDF

Epidemiological, economic and humanistic burden of cervical intraepithelial neoplasia in Europe: A systematic literature review.

Eur J Obstet Gynecol Reprod Biol X

March 2025

Value & Implementation Global Medical and Scientific Affairs, MSD, Rome, Italy.

Introduction: High-grade cervical intraepithelial neoplasia (CIN) is a premalignant lesion of the cervix caused by persistent human papillomavirus (HPV) infection, which can lead to cervical cancer. Despite ongoing primary prevention efforts, considerable burden of illness remains. This study assessed the epidemiological, economic, and humanistic burden associated with high-grade CIN among adult women in Europe.

View Article and Find Full Text PDF

Both women and men are now confronted with the grave threat of cancers caused by the human papillomavirus (HPV). It is estimated that 80% of women may encounter HPV over their lives. In the preponderance of cases involving anal, head and neck, oral, oropharyngeal, penile, vaginal, vulvar, and cervical malignancies, high-risk HPV (HR-HPV) is the causative agent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!